Continuing Education Activity

Vitamin A toxicity is an uncommon but clinically important condition caused by excessive exposure to preformed vitamin A or systemic retinoids. Toxicity may be acute, chronic, or teratogenic and can affect hepatic, skeletal, neurologic, dermatologic, metabolic, and fetal development outcomes. Clinical recognition may be challenging because symptoms such as fatigue, headache, dry skin, bone pain, nausea, laboratory abnormalities, and increased intracranial pressure can overlap with other disorders. The existing practice gap involves inconsistent identification of high-risk exposures, limited recognition of subclinical or chronic toxicity, and variable monitoring of patients receiving retinoid therapy or multiple vitamin A sources. This activity addresses the gap by reviewing risk factors, diagnostic evaluation, evidence-based treatment, complication prevention, patient education, and interprofessional coordination. Participants will gain actionable strategies to improve exposure assessment, diagnostic accuracy, laboratory interpretation, medication safety, and patient-centered outcomes.

Objectives:

• Identify the risk factors associated with excessive vitamin A intake, considering dietary sources, supplements, and medication history.
• Interpret serum retinol, fasting serum retinyl ester, liver function, lipid, renal function, electrolyte, and bone-related findings in the evaluation of suspected vitamin A toxicity.
• Apply evidence-based treatment strategies, including discontinuation of vitamin A sources, supportive care, retinoid dose adjustment or discontinuation, and complication-specific treatment.
• Coordinate care among clinicians, pharmacists, nurses, registered dietitians, hepatologists, endocrinologists, neurologists, ophthalmologists, and obstetricians and gynecologists to support early detection, monitoring, and prevention of vitamin A toxicity complications.

Access free multiple choice questions on this topic.

Introduction

Vitamin A is an essential fat-soluble nutrient required for vision, cellular differentiation, reproduction, and immune function. Vitamin A is obtained in 2 primary dietary forms: preformed vitamin A (retinol and its derivatives, including retinal, retinoic acid, and retinyl esters), found in animal-based foods, and provitamin A carotenoids (eg, β-carotene), found in plant-based sources and converted to active vitamin A in the body. In well-nourished populations, dietary intake from a mix of animal and plant sources is usually adequate to meet daily requirements. In resource-rich countries, however, excess intake of vitamin A and its synthetic derivatives is a more common concern than deficiency. Hypervitaminosis A results from toxic accumulation of preformed vitamin A, most commonly due to high-dose supplementation or excessive intake of vitamin A–rich foods. In contrast, dietary carotenoids are subject to regulated conversion and rarely cause toxicity.

Importantly, the term vitamin A toxicity also encompasses toxicity associated with systemic retinoid medications, such as isotretinoin and acitretin. Although these agents are chemically distinct from natural vitamin A, they act through the same retinoid receptors and produce overlapping clinical and pathophysiologic effects. Consequently, retinoid toxicity is often clinically indistinguishable from hypervitaminosis A and is considered part of the same clinical spectrum. Excess vitamin A exposure can cause acute and chronic toxicity, as well as well-established teratogenic effects with the potential for severe fetal malformations. Historically, vitamin A toxicity was first described in arctic explorers and Alaskan Natives who developed illness after consuming large quantities of polar bear and seal liver, which contain extremely high concentrations of preformed vitamin A.[1][2] This article reviews the etiology, epidemiology, pathophysiology, clinical manifestations, evaluation, treatment, complications, prevention, patient education, and the interprofessional healthcare team's role in recognizing and managing vitamin A toxicity.

Etiology

Vitamin A toxicity can be acute, chronic, or teratogenic. Acute toxicity typically results from ingesting very high doses (eg, greater than 2 million international units [IU] in adults or 350,000 IU in infants, approximately 25,000 IU/kg body weight). Chronic toxicity is more common and develops from prolonged intake of supratherapeutic doses, generally 25,000 to 50,000 IU per day over months, although lower doses may cause toxicity in susceptible individuals.[3] 

Hypervitaminosis A most commonly results from excessive intake of preformed vitamin A (retinol and retinyl esters) due to overuse of dietary supplements, excessive consumption of vitamin A–rich foods, or treatment with synthetic retinoids. Toxicity from dietary sources alone is uncommon but may occur with frequent ingestion of foods rich in preformed vitamin A, such as liver, fish liver oils, eggs, and dairy products. Preformed vitamin A is efficiently absorbed in the small intestine and stored in the liver, where it can accumulate and lead to toxicity.[4][5]

Systemic retinoids, including isotretinoin, bexarotene, and acitretin, are synthetic vitamin A analogs that can cause toxicity. Isotretinoin treats severe acne; bexarotene treats cutaneous T-cell lymphoma; and acitretin treats psoriasis. Although chemically distinct from retinol, these agents act on retinoid receptors and produce toxicity syndromes similar to hypervitaminosis A. Prolonged or excessive use increases the risk of accumulation and adverse effects, including teratogenicity. Patients taking systemic retinoids should avoid additional vitamin A supplementation to prevent additive toxicity.

Systemic vitamin A toxicity from standard topical retinoid use is not well documented in the medical literature. Available evidence indicates that topical retinoids, such as tretinoin for acne, have minimal systemic absorption, making systemic toxicity highly unlikely under normal use. Although topical retinoids are not recommended during pregnancy as a precaution, available human evidence does not demonstrate an increased risk of major congenital malformations from inadvertent first-trimester exposure.[6] In contrast, provitamin A carotenoids (eg, β-carotene), plant pigments found in leafy greens and brightly colored fruits and vegetables such as carrots and sweet potatoes, are converted to active vitamin A through regulated processes. Because their absorption and conversion are subject to feedback control, toxicity from these sources is extremely rare.[7][8] 

Epidemiology

Vitamin A toxicity is uncommon overall, with historically reported incidence in the US averaging fewer than 10 cases per year from 1976 to 1987.[3] However, the true prevalence is likely underestimated and varies significantly across populations and exposure patterns. Findings from emerging data suggest higher rates of subclinical or unrecognized toxicity, particularly in populations with overlapping sources of vitamin A intake.[9] 

In resource-rich countries, toxicity most often results from excessive use of dietary supplements that exceed recommended daily allowances. In contrast, in regions where vitamin A deficiency is prevalent, large-scale supplementation and food fortification programs may increase the risk of toxicity if dosing guidelines are not strictly followed.[10][11] Populations that frequently consume vitamin A–rich organ meats, such as liver, may also be at increased risk. However, reported cases remain rare and are not considered a major public health concern.[12][13][14]

The prevalence of hypervitaminosis A varies widely depending on the assessment method and population characteristics. In a US study of adult cadavers, 33% had elevated hepatic vitamin A levels (≥1 μmol/g liver), suggesting a high prevalence of subclinical toxicity. In settings with combined supplementation and fortification programs, substantially higher rates have been observed; for example, 59% of Zambian children receiving multiple vitamin A interventions had evidence of hypervitaminosis A, and 16% had biochemical markers of toxicity. Similarly, 72.5% of South African children who frequently consumed liver had elevated retinyl esters consistent with excess vitamin A exposure.[9] Infants and children are more susceptible due to smaller body size and lower tolerance for high doses. Accidental ingestion of supplements is a common cause of acute toxicity in this group.[15] 

Pregnant women are at risk of teratogenic effects with excessive intake, and adverse outcomes have been reported at doses as low as 25,000 IU per day. Additional at-risk groups include individuals with underlying liver disease, hyperlipidemia, high alcohol intake, or conditions affecting vitamin A metabolism, as well as older adults.[16] No consistent sex-based differences have been observed.

Pathophysiology

Vitamin A toxicity results from excessive accumulation of preformed vitamin A and its retinoid derivatives, disrupting normal storage, transport, and signaling pathways. Under physiologic conditions, vitamin A is stored in hepatic stellate cells and transported in a protein-bound form. With excessive intake, hepatic storage capacity is exceeded, increasing circulating free retinoids that cause cellular toxicity via oxidative stress and inflammation.[5] 

The underlying mechanism involves saturation of plasma transport proteins and hepatic storage systems, leading to abnormal retinoid distribution in peripheral tissues. Retinoid accumulation promotes oxidative stress by generating reactive oxygen species and activating inflammatory pathways, including transforming growth factor–beta (TGF-β) and nuclear factor kappa B (NF-κB), resulting in hepatocellular injury, stellate cell activation, and progressive fibrosis that may progress to cirrhosis.[5] Additionally, excess vitamin A stimulates osteoclast activity, leading to bone resorption and, in some cases, hypercalcemia.[17] 

Toxicity

Vitamin A toxicity manifests as acute, chronic, and teratogenic syndromes, reflecting differences in exposure and underlying mechanisms.

Acute toxicity: Acute toxicity results from the ingestion of a very large dose that overwhelms normal plasma transport mechanisms. Under physiologic conditions, retinol circulates bound to retinol-binding protein and transthyretin, which regulate tissue delivery and limit toxicity. With massive intake, these transport systems become saturated, leading to increased circulating unbound retinoids and abnormal distribution to peripheral tissues. These excess retinoids exert direct cellular toxicity through destabilization of cell membranes, generation of reactive oxygen species, mitochondrial dysfunction, and activation of apoptotic pathways. Together, these processes result in transient but potentially severe multiorgan effects.[5][18]

Chronic toxicity: Retinol accumulation leads to multisystem involvement. Hepatic injury and disruption of liver metabolism range from biochemical abnormalities to fibrosis and cirrhosis.[5] Skeletal effects result from increased bone resorption and abnormal bone remodeling, leading to hyperostosis, calcification, and increased risk of fractures.[19][20] Systemic retinoids cause dose-dependent toxicity through similar receptor-mediated mechanisms, contributing to metabolic, neurologic, and hepatic disturbances.

The exact mechanism by which retinoid toxicity causes intracranial hypertension is incompletely understood, but several proposed pathways involve alterations in cerebrospinal fluid dynamics. Natural vitamin A toxicity is unlikely to be a contributory factor in idiopathic intracranial hypertension because serum and cerebrospinal fluid vitamin A levels and metabolite levels are not consistently elevated in patients with idiopathic intracranial hypertension.[21][22][23]  

Teratogenic toxicity: Teratogenicity stems from disruption of retinoid-regulated gene expression during embryogenesis. Vitamin A is critical for regulating gene expression and guiding cell differentiation in embryonic development. The embryo is especially susceptible to the teratogenic effects of excessive vitamin A and retinoids during the first trimester, a period of rapid organogenesis. Retinoids disrupt neural crest cell migration and axial patterning by altering the expression of homeobox (HOX) genes, leading to characteristic congenital malformations.[8][24][25][26]

Histopathology

Hypervitaminosis A affects multiple organ systems, with the most well-characterized histopathologic changes occurring in the liver. Additional findings may involve the bone and skin, depending on the severity and duration of exposure. Diagnosis often relies on liver biopsy, particularly when clinical suspicion is low.

Liver 

Vitamin A hepatotoxicity encompasses a continuum of histopathologic changes, ranging from early steatosis to advanced fibrosis and cirrhosis. A hallmark histologic feature is hypertrophy and hyperplasia of hepatic stellate cells (Ito cells), reflecting the central role of stellate cells in vitamin A storage. With excessive exposure, stellate cells enlarge and become lipid-laden, often exhibiting characteristic fluorescence under ultraviolet light.[5][27] As toxicity progresses, perisinusoidal fibrosis becomes the defining pathologic feature, characterized by collagen and reticulin deposits within the space of Disse that form basement membrane–like material. The extent of fibrosis correlates with cumulative vitamin A exposure, supporting a dose-dependent relationship.[21][27][28]

Bone

Excess vitamin A stimulates osteoclast formation on periosteal surfaces, inhibits osteoblast mineralization, and reduces levels of key transcription factors required for osteoblast maturation.[29] Skeletal findings include osteoporosis and cortical bone thickening, reflecting increased bone turnover and abnormal remodeling. Bone histopathology shows increased osteoclastic resorption, periosteal bone loss, and impaired mineralization.[30]

Skin

Cutaneous histopathology may show epidermal hyperplasia and features of exfoliative dermatitis.[31][32]

Toxicokinetics

Pharmacokinetics

The toxicokinetics of vitamin A toxicity reflect alterations in the nutrient’s normal absorption, distribution, metabolism, and elimination, particularly when physiologic storage and transport mechanisms become saturated.

Absorption: Vitamin A is absorbed in the small intestine as preformed vitamin A (retinol and retinyl esters) from animal-derived foods and supplements and as provitamin A carotenoids from plant sources. Absorption is enhanced by dietary fat. In toxic states, absorption of preformed vitamin A remains efficient and is not tightly regulated, contributing to excess systemic levels.

Distribution: Following absorption, vitamin A is transported to the liver, where it is stored in hepatic stellate cells as retinyl esters. Under normal conditions, retinol is released into the circulation bound to retinol-binding protein and transthyretin. With excessive intake, hepatic storage capacity is exceeded, leading to increased circulating free retinoids and unbound retinol, which can deposit in peripheral tissues and contribute to toxicity.

Metabolism: Retinol is converted intracellularly to its active metabolites, retinal and retinoic acid, which regulate gene expression. Lecithin retinol acyltransferase (LRAT) facilitates esterification for hepatic storage, while cellular retinol-binding proteins regulate intracellular trafficking.[33] In toxicity, dysregulation of these pathways contributes to the accumulation of active retinoids and enhanced biologic effects at the nuclear receptor level.

Elimination: Vitamin A and its metabolites are eliminated predominantly through biliary excretion into the feces, with minimal renal clearance. Because vitamin A is fat-soluble and extensively stored in the liver, the nutrient has a prolonged half-life. In the context of toxicity, these characteristics lead to sustained elevations even after discontinuation of vitamin A exposure, and clinical effects may persist for weeks to months.

History and Physical

History

A thorough history often reveals excessive intake of preformed vitamin A from dietary supplements, fortified foods, or vitamin A–rich foods (eg, liver), or the use of systemic retinoids (eg, isotretinoin, acitretin). Patients should also be asked about the duration and dose of exposure to determine whether toxicity is acute or chronic.[34]

Acute toxicity: Acute toxicity typically results from ingesting a large dose, usually greater than 100,000 retinol activity equivalents, within a short period, often from supplements or high-dose medications. Patients commonly report:

• Nausea and vomiting
• Headache and dizziness
• Blurred vision
• Irritability
• Impaired coordination [18]

Chronic toxicity: Chronic toxicity results from prolonged excessive intake, usually from high-dose supplements or sustained dietary exposure.[34] Common symptoms include:

• Fatigue and malaise
• Anorexia and weight loss
• Dry skin and hair loss
• Bone and joint pain
• Headache, vision changes, nausea, and vomiting due to increased intracranial pressure

Teratogenic exposure: A history of vitamin A excess during pregnancy, most commonly from systemic retinoid use, is associated with a high risk of fetal malformations.[8][24][25][24] A detailed medication and supplement history is critical for women of childbearing age. The risk is highest in the first trimester, when organogenesis occurs. No safe threshold for oral retinoid exposure during pregnancy has been established.[25]

Physical Examination

General physical examination findings vary depending on the duration and severity of toxicity. Findings may include:

• Dryness of the conjunctiva and mucous membranes
• Scaly or xerotic skin
• Alopecia
• Hepatomegaly
• Bone tenderness

Acute toxicity: 

• Mucocutaneous findings such as cheilitis, dry lips, and dry skin
• Neurologic findings, including impaired coordination
• Signs of increased intracranial pressure, including papilledema [18][35]

Chronic toxicity:

• Xerosis, fissuring, and desquamation of the skin
• Alopecia and brittle nails
• Skeletal tenderness or deformities related to hyperostosis and fractures [19][20]
• Hepatomegaly, reflecting underlying liver involvement [21] 
• Signs of increased intracranial pressure, including papilledema [18][35] 

Teratogenic effects (fetal and neonatal findings):

• Craniofacial anomalies (eg, cleft lip and palate)
• Central nervous system abnormalities (eg, microcephaly, hydrocephalus)
• Cardiac defects
• Extremity abnormalities
• Genitourinary malformations [8][24][25][24]

Evaluation

Diagnostic evaluation of suspected vitamin A toxicity is guided by clinical history and physical examination findings, with targeted laboratory and imaging studies used to confirm the diagnosis and assess severity.

Laboratory Evaluation

Vitamin A levels:

• Serum retinol levels, commonly reported as serum vitamin A levels, may be within the reference range (1 to 3 µmol/L) or only mildly elevated due to homeostatic regulation and do not reliably reflect total body vitamin A stores.[5] 
• Serum retinol levels higher than 3 µmol/L have been associated with increased fracture risk.[36]
• Fasting serum retinyl esters (reference value: 0.2 µmol/L; elevated levels indicate toxicity) are a more reliable marker, particularly when expressed as a percentage of total serum retinol.[3] In toxicity, excess vitamin A circulates as retinyl esters bound to lipoproteins rather than retinol bound to retinol-binding protein.[37] 

Liver function tests:

• Elevated alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase levels may indicate hepatic injury. 
• Elevations are often mild and reversible but may progress to fibrosis or cirrhosis with prolonged exposure.[21]

Lipid profile:

• Hypertriglyceridemia is the most common laboratory abnormality associated with vitamin A toxicity and oral retinoid use.
• Increased low-density lipoprotein and total cholesterol levels are also frequently observed.[38][39] 

Additional laboratory findings:

• Hematologic abnormalities, including leukocytosis, thrombocytopenia, and anemia
• Renal function abnormalities, including elevated blood urea nitrogen and creatinine
• Electrolyte abnormalities, including hypercalcemia
• Bone turnover markers, including an elevated serum alkaline phosphatase level

Medication-specific monitoring:

• Patients receiving isotretinoin should undergo periodic monitoring of lipid and liver enzyme levels.[40][41]
• Bexarotene therapy requires monitoring of thyroid function (free thyroxine) and frequent lipid assessment.[42]
• Renal function should be checked regularly in patients receiving etretinate, particularly those with preexisting kidney disease.[43]
• Patients who can become pregnant must have 2 negative pregnancy test results before initiating isotretinoin, with continued pregnancy testing during treatment and 1 month after discontinuing therapy.[44] 

Imaging and Specialized Testing

Hepatic evaluation:

Liver biopsy may be indicated when the diagnosis is uncertain or to assess the severity of hepatic injury.

Neurologic evaluation:

Patients with persistent headache or visual symptoms should be evaluated for increased idiopathic intracranial pressure, also known as pseudotumor cerebri, including ophthalmologic examination for papilledema and brain imaging.

Skeletal imaging:

Radiographs may demonstrate cortical thickening of long bones, periosteal new bone formation, demineralization, and premature epiphyseal closure in children. Skull imaging may show calvarial thinning and suture diastasis.[45] 

Treatment / Management

Management of vitamin A toxicity is primarily supportive, focusing on the immediate discontinuation of all sources of vitamin A, including dietary supplements, fortified foods, and systemic retinoids.[5] Patients should also avoid foods high in preformed vitamin A (eg, liver, fish liver oil, dairy, and eggs) until toxicity resolves. Because retinol has a long half-life and substantial hepatic storage, clinical improvement may take weeks to months even after intake is stopped.[17]

Acute Toxicity

Acute toxicity is typically self-limited. Acute toxicity is typically self limited. Discontinuing vitamin A sources is the primary intervention. Supportive care includes antiemetics for nausea and vomiting and analgesics for headache or discomfort.[5] Most symptoms resolve within 24 hours of stopping exposure.[46] 

Chronic Toxicity

Chronic toxicity requires ongoing monitoring and supportive treatment. Regular assessment of vital signs, clinical status, and laboratory abnormalities is recommended. Severe cases may require hospitalization. Supportive care measures include emollients or moisturizers for xerosis and skin fissuring, artificial tears or lubricating eye drops for dry eyes, and analgesics for bone and joint pain.

Hepatic involvement: Clinicians should monitor liver function tests and consider imaging as indicated. Limiting vitamin A intake is essential. Antioxidant therapies (eg, acetylcysteine) and antifibrotic approaches have been proposed but remain investigational.[5]

Medication-Induced Toxicity (Retinoids)

Medication-induced toxicity depends on severity and the specific agent. Dose reduction or discontinuation of the offending retinoid is the primary intervention. Hypertriglyceridemia is common with retinoids and may require monitoring or lipid-lowering therapy when elevations are mild. Severe elevations (≥800 mg/dL) warrant discontinuation or dose reduction and consideration of lipid-lowering agents to prevent pancreatitis.[47] Bexarotene-associated dyslipidemia may be treated with statins or fibrates; therapy should be discontinued if levels remain greater than 3 times the upper limit of normal.[47] 

Management of Complications

Hypercalcemia: Treatment may include loop diuretics (eg, furosemide), intravenous fluid hydration, calcitonin for acute treatment, and bisphosphonates (eg, pamidronate) for sustained control. [48] 

Idiopathic intracranial hypertension (pseudotumor cerebri): Treatment includes discontinuing vitamin A or retinoid therapy. Acetazolamide, serial lumbar punctures, or shunting may be required in severe cases.[18]

Monitoring

Serial laboratory monitoring, including liver function tests and lipid profiles, is recommended for patients with moderate to severe toxicity or those receiving retinoid therapy.[5][48] Serum retinol levels may be monitored, but they do not reliably reflect total body stores. Monitoring should be guided by clinical severity, exposure history, and complications.

Teratogenic Toxicity

Vitamin A–related teratogenic effects result in permanent structural abnormalities. Treatment is supportive and depends on the specific organ systems affected. Care often requires interdisciplinary and surgical procedural support.

Differential Diagnosis

The differential diagnosis of hypervitaminosis A includes conditions that present with overlapping hepatic, metabolic, neurologic, dermatologic, and systemic findings:

• Hepatic disorders: Acute liver injury due to viral hepatitis, alcohol use, or drug-induced hepatotoxicity
• Hypercalcemia: Primary hyperparathyroidism, malignant neoplasm, or excessive calcium or vitamin D intake
• Endocrine disorders: Hypothyroidism due to primary thyroid disease or medication effects
• Renal disease: Chronic kidney disease from diabetes mellitus, hypertension, glomerulonephritis, or polycystic kidney disease
• Neurologic conditions: Idiopathic intracranial hypertension unrelated to vitamin A exposure
• Dermatologic conditions: Exfoliative dermatitis and other inflammatory or desquamating skin disorders

Because many symptoms of vitamin A toxicity are nonspecific, including fatigue, rash, arthralgia, and laboratory abnormalities involving the liver and kidneys, systemic conditions such as systemic lupus erythematosus should also be considered in the appropriate clinical context.

Prognosis

The prognosis of hypervitaminosis A depends on the severity of toxicity, duration of exposure, and extent of organ involvement. In most patients, discontinuing excess vitamin A intake leads to gradual symptom resolution, with full recovery expected. Common manifestations, such as dry skin, headache, and nausea, typically improve over weeks to months without long-term sequelae. Acute toxicity is typically self-limited, with symptoms resolving rapidly, often within 24 h after intake stops.[49] 

Chronic toxicity has a more variable course. Although many manifestations are reversible with prompt recognition and discontinuation of vitamin A, prolonged exposure can lead to persistent or permanent complications. Hepatic injury may progress to fibrosis or cirrhosis, which can be irreversible in advanced stages.[5] Skeletal abnormalities, including decreased bone density and increased fracture risk, may persist despite treatment. Neurologic complications, such as pseudotumor cerebri, can cause lasting visual impairment. Furthermore, pediatric considerations are especially important because premature epiphyseal closure can lead to permanent growth impairment. Overall, the prognosis is favorable with early recognition and intervention but becomes progressively worse with delayed diagnosis, particularly once significant organ damage has developed.

Complications

Vitamin A toxicity can lead to multisystem complications, especially with prolonged or high-dose exposure.

Hepatic Complications

• Progressive liver injury, ranging from fibrosis to cirrhosis
• Portal hypertension may occur in advanced disease

Skeletal Complications

• Increased bone resorption and decreased bone formation
• Osteoporosis and increased fracture risk
• Hyperostosis and abnormal bone remodeling

Neurologic Complications

• Pseudotumor cerebri may lead to persistent visual disturbances and, in severe cases, permanent vision loss.

Teratogenic Complications

• Craniofacial abnormalities (eg, cleft lip and palate)
• Central nervous system malformations (eg, microcephaly, hydrocephalus)
• Cardiac defects (eg, transposition of the great vessels)
• Limb abnormalities
• Genitourinary anomalies [8]

Hematologic Complications

• Anemia
• Thrombocytopenia
• Leukocytosis

Medication-Related Complications

• Hypothyroidism, particularly with bexarotene, is typically reversible after discontinuation.[50] 
• Evidence does not consistently support a causal association between isotretinoin and psychiatric disorders such as depression or suicide.[51]

Deterrence and Patient Education

Patient education regarding vitamin A toxicity is a shared responsibility among healthcare professionals, including clinicians, advanced practice clinicians, nurses, registered dietitians, and pharmacists. Education should focus on safe intake, recognition of risk factors, and prevention of excessive exposure. Patients should be counseled to maintain a balanced diet and avoid excessive intake of preformed vitamin A.

Dietary Counseling and Safe Intake

Patients should be counseled to maintain a balanced diet and avoid excessive intake of preformed vitamin A. They should be cautioned that intake from supplements and fortified foods may exceed recommended levels, particularly in resource-rich countries.[3]

The richest dietary sources include:

• Liver and organ meats, which contain very high concentrations (3000–15,000 mcg retinol per 100 g)
• Fish and fish oils 
• Dairy products: milk (30–70 mcg retinol/100 mL), cheese (179–319 mcg/100 g depending on fat content), butter, and yogurt
• Eggs (100–300 mcg retinol per 100 g)[52]

Most diets contain both preformed vitamin A and provitamin A carotenoids. Preformed vitamin A is found in animal-based foods and fortified products, whereas provitamin A carotenoids are abundant in leafy greens and brightly colored fruits and vegetables such as carrots, papayas, and sweet potatoes. Patients should be informed that toxicity is primarily associated with excess preformed vitamin A, while plant-based carotenoids are generally safe due to regulated conversion. The recommended dietary allowance (RDA) for vitamin A is measured in retinol activity equivalents (RAE) to account for the different bioactivities of retinol and provitamin A carotenoids. One RAE is equivalent to 1 mcg of retinol or 3 international units (IU). International units remain the most commonly used unit in clinical practice for discussions of vitamin A toxicity. Retinol activity equivalents are the preferred unit for dietary intake recommendations and nutritional assessment.

• Recommended dietary allowance (RDA):

  • 700 RAE/day (2333 IU) for adult women
  • 900 RAE/day (300 IU) for adult men
  • 750–770 RAE/day (2500-2567 IU) during pregnancy
  • 1200–1300 RAE/day (4000-4333IU) during lactation
• Tolerable upper intake level (UL):

  • 3000 RAE/day (10,000 IU) for adults [3]

Medication Counseling

Pharmacists and prescribing clinicians should educate patients about medications containing vitamin A and its derivatives, including retinoids and both prescription and over-the-counter products. Counseling should emphasize adherence to prescribed dosing and duration, avoidance of concurrent vitamin A supplementation unless directed, and awareness of potential adverse effects and toxicity symptoms. Medication counseling is especially important for patients taking systemic retinoids or multiple supplements that may contain vitamin A.

Special Populations

Pregnant women and women of childbearing potential: Pregnant women should not ingest excessive vitamin A. They should consult clinicians before taking any supplements and must never use systemic retinoids due to the risk of severe teratogenic effects. Patients of childbearing age prescribed retinoids should use effective contraception and follow monitoring guidelines.

Prevention and Early Recognition

Patients should be advised to avoid high-dose vitamin A supplements unless medically prescribed. They should limit frequent consumption of vitamin A–rich organ meats and report symptoms such as persistent headache, vision changes, dry skin, or bone pain. When toxicity is suspected, clinicians should counsel patients to discontinue vitamin A sources and seek medical evaluation immediately. Early recognition and intervention are essential to prevent complications.

Enhancing Healthcare Team Outcomes

Preventing and treating vitamin A toxicity requires coordinated, systems-based care from an interprofessional healthcare team. The focus is on risk identification, medication safety, monitoring, and care coordination, rather than patient-directed counseling alone. Primary care clinicians and advanced practice clinicians are responsible for early recognition and risk stratification, including obtaining a comprehensive history of dietary intake, supplements, and medications; identifying high-risk populations (eg, patients using retinoids, those with liver disease, or pregnant women); and initiating appropriate diagnostic evaluation and treatment.

Pharmacists play a critical role in medication reconciliation and safety surveillance. They identify duplicate or excessive sources of vitamin A across prescription and over-the-counter products, evaluate for drug-nutrient interactions, and assist with dose adjustments or discontinuation of retinoid therapies when toxicity is suspected. Pharmacists also support monitoring protocols for patients receiving systemic retinoids. Nursing staff contribute to ongoing clinical monitoring and care coordination, including assessing for evolving symptoms, reinforcing adherence to treatment plans, and communicating clinical changes to the care team.

Registered dietitians provide individualized nutritional assessment and treatment, particularly for patients with dietary risk factors or those requiring restriction of preformed vitamin A intake while maintaining adequate nutrition. Specialist involvement is guided by complications and may include hepatology for hepatic injury, endocrinology for hypercalcemia or metabolic disturbances, neurology or ophthalmology for idiopathic intracranial hypertension, and obstetrics and gynecology for pregnancy-related risk management. For patients who can become pregnant, coordinated protocols are essential. Prescribers, pharmacists, and nursing staff must ensure pregnancy screening, documentation, and adherence to risk-mitigation strategies when prescribing systemic retinoids. Effective interprofessional care relies on clear communication, shared documentation, and structured follow-up. These practices reduce preventable toxicity, improve early detection, and optimize patient outcomes.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

SOLER-BECHARA J, SOSCIA JL. CHRONIC HYPERVITAMINOSIS A. REPORT OF A CASE IN AN ADULT. Arch Intern Med. 1963 Oct;112:462-6. [PubMed: 14051363]

2.

Rodahl K, Moore T. The vitamin A content and toxicity of bear and seal liver. Biochem J. 1943 Jul;37(2):166-8. [PMC free article: PMC1257872] [PubMed: 16747610]

3.

Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. Am J Clin Nutr. 2006 Feb;83(2):191-201. [PubMed: 16469975]

4.

Hunt JR. Teratogenicity of high vitamin A intake. N Engl J Med. 1996 May 02;334(18):1197. [PubMed: 8602195]

5.

Pestalardo ML, Bevilacqua CS, Amante MF. Vitamin A toxicity and hepatic pathology: A comprehensive review. World J Hepatol. 2025 Aug 27;17(8):107738. [PMC free article: PMC12400428] [PubMed: 40901583]

6.

Refsum E, Furu K, Cesta CE, Nørgaard M, Wittström F, Zoega H, Ulrichsen SP, Cohen JM. Topical retinoid use in women of reproductive age and risk of major congenital malformations in exposed pregnancies: a Nordic cohort study. Br J Dermatol. 2026 Mar 19;194(4):640-647. [PubMed: 41365815]

7.

Strobel M, Tinz J, Biesalski HK. The importance of beta-carotene as a source of vitamin A with special regard to pregnant and breastfeeding women. Eur J Nutr. 2007 Jul;46 Suppl 1:I1-20. [PubMed: 17665093]

8.

Bastos Maia S, Rolland Souza AS, Costa Caminha MF, Lins da Silva S, Callou Cruz RSBL, Carvalho Dos Santos C, Batista Filho M. Vitamin A and Pregnancy: A Narrative Review. Nutrients. 2019 Mar 22;11(3) [PMC free article: PMC6470929] [PubMed: 30909386]

9.

Tanumihardjo SA, Kaliwile C, Boy E, Dhansay MA, van Stuijvenberg ME. Overlapping vitamin A interventions in the United States, Guatemala, Zambia, and South Africa: case studies. Ann N Y Acad Sci. 2019 Jun;1446(1):102-116. [PMC free article: PMC7999526] [PubMed: 30265402]

10.

Sauvant P, Féart C, Atgié C. Vitamin A supply to mothers and children: challenges and opportunities. Curr Opin Clin Nutr Metab Care. 2012 May;15(3):310-4. [PubMed: 22406743]

11.

Arlappa N. Vitamin A supplementation policy: A shift from universal to geographical targeted approach in India considered detrimental to health and nutritional status of under 5 years children. Eur J Clin Nutr. 2023 Jan;77(1):1-6. [PMC free article: PMC8959797] [PubMed: 35347255]

12.

Ball MD, Furr HC, Olson JA. Acyl coenzyme A:retinol acyltransferase activity and the vitamin A content of polar bear (Ursus maritimus) liver. Comp Biochem Physiol B. 1986;84(4):513-7. [PubMed: 3757481]

13.

Senoo H, Imai K, Mezaki Y, Miura M, Morii M, Fujiwara M, Blomhoff R. Accumulation of vitamin A in the hepatic stellate cell of arctic top predators. Anat Rec (Hoboken). 2012 Oct;295(10):1660-8. [PubMed: 22907891]

14.

Mahoney CP, Margolis MT, Knauss TA, Labbe RF. Chronic vitamin A intoxication in infants fed chicken liver. Pediatrics. 1980 May;65(5):893-7. [PubMed: 7189278]

15.

Lagacé M, Oskoui M, Myers K. Not a Benign Vitamin: Infant with Vitamin A Toxicity and Acute Intracranial Hypertension. Can J Neurol Sci. 2024 Mar;51(2):308-309. [PubMed: 36503562]

16.

Hathcock JN, Hattan DG, Jenkins MY, McDonald JT, Sundaresan PR, Wilkening VL. Evaluation of vitamin A toxicity. Am J Clin Nutr. 1990 Aug;52(2):183-202. [PubMed: 2197848]

17.

Borgan SM, Khan LZ, Makin V. Hypercalcemia and vitamin A: A vitamin to keep in mind. Cleve Clin J Med. 2022 Feb 01;89(2):99-105. [PubMed: 35105698]

18.

Chisholm JT, Abou-Jaoude MM, Hessler AB, Sudhakar P. Pseudotumor Cerebri Syndrome with Resolution After Discontinuing High Vitamin A Containing Dietary Supplement: Case Report and Review. Neuroophthalmology. 2018 Jun;42(3):169-175. [PMC free article: PMC5958954] [PubMed: 29796052]

19.

Scheven BA, Hamilton NJ. Retinoic acid and 1,25-dihydroxyvitamin D3 stimulate osteoclast formation by different mechanisms. Bone. 1990;11(1):53-9. [PubMed: 2331432]

20.

Genaro Pde S, Martini LA. Vitamin A supplementation and risk of skeletal fracture. Nutr Rev. 2004 Feb;62(2):65-7. [PubMed: 15080368]

21.

Nollevaux MC, Guiot Y, Horsmans Y, Leclercq I, Rahier J, Geubel AP, Sempoux C. Hypervitaminosis A-induced liver fibrosis: stellate cell activation and daily dose consumption. Liver Int. 2006 Mar;26(2):182-6. [PubMed: 16448456]

22.

McGeeney BE, Friedman DI. Pseudotumor cerebri pathophysiology. Headache. 2014 Mar;54(3):445-58. [PubMed: 24433163]

23.

Libien J, Kupersmith MJ, Blaner W, McDermott MP, Gao S, Liu Y, Corbett J, Wall M., NORDIC Idiopathic Intracranial Hypertension Study Group. Role of vitamin A metabolism in IIH: Results from the idiopathic intracranial hypertension treatment trial. J Neurol Sci. 2017 Jan 15;372:78-84. [PMC free article: PMC5290478] [PubMed: 28017254]

24.

Rothman KJ, Moore LL, Singer MR, Nguyen US, Mannino S, Milunsky A. Teratogenicity of high vitamin A intake. N Engl J Med. 1995 Nov 23;333(21):1369-73. [PubMed: 7477116]

25.

Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, Curry CJ, Fernhoff PM, Grix AW, Lott IT. Retinoic acid embryopathy. N Engl J Med. 1985 Oct 03;313(14):837-41. [PubMed: 3162101]

26.

Marshall H, Studer M, Pöpperl H, Aparicio S, Kuroiwa A, Brenner S, Krumlauf R. A conserved retinoic acid response element required for early expression of the homeobox gene Hoxb-1. Nature. 1994 Aug 18;370(6490):567-71. [PubMed: 7914354]

27.

Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology. 1991 Jun;100(6):1701-9. [PubMed: 2019375]

28.

Zafrani ES, Bernuau D, Feldmann G. Peliosis-like ultrastructural changes of the hepatic sinusoids in human chronic hypervitaminosis A: report of three cases. Hum Pathol. 1984 Dec;15(12):1166-70. [PubMed: 6500549]

29.

Henning P, Westerlund A, Horkeby K, Lionikaite V, Nilsson KH, Movérare-Skrtic S, Conaway HH, Lerner UH. Vitamin A enhanced periosteal osteoclastogenesis is associated with increased number of tissue-derived macrophages/osteoclast progenitors. J Biol Chem. 2024 Jun;300(6):107308. [PMC free article: PMC11163173] [PubMed: 38657862]

30.

Lind T, Sundqvist A, Hu L, Pejler G, Andersson G, Jacobson A, Melhus H. Vitamin a is a negative regulator of osteoblast mineralization. PLoS One. 2013;8(12):e82388. [PMC free article: PMC3858291] [PubMed: 24340023]

31.

Inkeles SB, Connor WE, Illingworth DR. Hepatic and dermatologic manifestations of chronic hypervitaminosis A in adults. Report of two cases. Am J Med. 1986 Mar;80(3):491-6. [PubMed: 2937294]

32.

Chen G, Weiskirchen S, Weiskirchen R. Vitamin A: too good to be bad? Front Pharmacol. 2023;14:1186336. [PMC free article: PMC10239981] [PubMed: 37284305]

33.

Moise AR, Noy N, Palczewski K, Blaner WS. Delivery of retinoid-based therapies to target tissues. Biochemistry. 2007 Apr 17;46(15):4449-58. [PMC free article: PMC2562735] [PubMed: 17378589]

34.

Horowitz BZ. Did hypervitaminosis A have a role in Mawson's ill-fated Antarctic exploration? Clin Toxicol (Phila). 2022 Nov;60(11):1277-1281. [PubMed: 36286587]

35.

Shaia JK, Rock JR, Singh RP, Talcott KE, Cohen DA. Drug-Induced Intracranial Hypertension: The Adverse Effects of Acne Medications and Topical Retinoids. J Neuroophthalmol. 2025 Jun 01;45(2):177-182. [PubMed: 39148176]

36.

Michaëlsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med. 2003 Jan 23;348(4):287-94. [PubMed: 12540641]

37.

Olsen K, Suri DJ, Davis C, Sheftel J, Nishimoto K, Yamaoka Y, Toya Y, Welham NV, Tanumihardjo SA. Serum retinyl esters are positively correlated with analyzed total liver vitamin A reserves collected from US adults at time of death. Am J Clin Nutr. 2018 Nov 01;108(5):997-1005. [PMC free article: PMC6692705] [PubMed: 30475970]

38.

Koo J, Nguyen Q, Gambla C. Advances in psoriasis therapy. Adv Dermatol. 1997;12:47-72; discussion 73. [PubMed: 8973735]

39.

Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC., Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001 May;137(5):581-93. [PubMed: 11346336]

40.

Goldsmith LA, Bolognia JL, Callen JP, Chen SC, Feldman SR, Lim HW, Lucky AW, Reed BR, Siegfried EC, Thiboutot DM, Wheeland RG., American Academy of Dermatology. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol. 2004 Jun;50(6):900-6. [PubMed: 15153892]

41.

Sammartano A, Bertoncini L, Barbuti A, Ippolito L. A suspected hypervitaminosis A. Acta Biomed. 2023 Jun 14;94(3):e2023098. [PMC free article: PMC10308465] [PubMed: 37326274]

42.

Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007 Sep;157(3):433-40. [PubMed: 17553039]

43.

Cribier B, Welsch M, Heid E. Renal impairment probably induced by etretinate. Dermatology. 1992;185(4):266-8. [PubMed: 1477420]

44.

Cook MK, Perche PO, Feldman SR. The use of oral vitamin A in acne management: a review. Dermatol Online J. 2022 Oct 15;28(5) [PubMed: 36809126]

45.

Lind T, Öhman C, Calounova G, Rasmusson A, Andersson G, Pejler G, Melhus H. Excessive dietary intake of vitamin A reduces skull bone thickness in mice. PLoS One. 2017;12(4):e0176217. [PMC free article: PMC5398668] [PubMed: 28426756]

46.

Nagai K, Hosaka H, Kubo S, Nakabayashi T, Amagasaki Y, Nakamura N. Vitamin A toxicity secondary to excessive intake of yellow-green vegetables, liver and laver. J Hepatol. 1999 Jul;31(1):142-8. [PubMed: 10424294]

47.

Wiegand UW, Chou RC. Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S25-33. [PubMed: 9703120]

48.

O'Neal S, Foster TP, Bhatt A, Lossius MN, Dayton K. Hypercalcemia from hypervitaminosis A in a child with autism. J Pediatr Endocrinol Metab. 2020 Jul 13; [PubMed: 32658863]

49.

Hombali AS, Solon JA, Venkatesh BT, Nair NS, Peña-Rosas JP. Fortification of staple foods with vitamin A for vitamin A deficiency. Cochrane Database Syst Rev. 2019 May 10;5(5):CD010068. [PMC free article: PMC6509778] [PubMed: 31074495]

50.

Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999 Apr 08;340(14):1075-9. [PubMed: 10194237]

51.

Bigby M. Does isotretinoin increase the risk of depression? Arch Dermatol. 2008 Sep;144(9):1197-9; discussion 1234-5. [PubMed: 18794466]

52.

Vanek VW, Borum P, Buchman A, Fessler TA, Howard L, Jeejeebhoy K, Kochevar M, Shenkin A, Valentine CJ., Novel Nutrient Task Force, Parenteral Multi-Vitamin and Multi–Trace Element Working Group. American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. Nutr Clin Pract. 2012 Aug;27(4):440-91. [PubMed: 22730042]

Disclosure: Sharon Daley declares no relevant financial relationships with ineligible companies.

Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies.